Comparative Pharmacology
Head-to-head clinical analysis: BRETYLIUM TOSYLATE versus CORDARONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLIUM TOSYLATE versus CORDARONE.
BRETYLIUM TOSYLATE vs CORDARONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate is a class III antiarrhythmic agent that prolongs the action potential duration and refractory period by blocking potassium channels. It also initially causes norepinephrine release, leading to transient hypertension and increased contractility, followed by adrenergic neuron blockade, resulting in hypotension and reduced contractility.
Class III antiarrhythmic agent; prolongs action potential duration and refractory period via blockade of potassium channels; also exhibits class I, II, and IV properties including sodium channel blockade, non-competitive beta-adrenergic blockade, and calcium channel blockade.
For ventricular tachycardia/fibrillation: 5-10 mg/kg IV bolus over 1-2 minutes, may repeat every 15-30 minutes up to 30 mg/kg total. Maintenance: 5-10 mg/kg IV every 6 hours or 0.5-2 mg/min continuous infusion. Intramuscular: 5-10 mg/kg undiluted, may repeat every 1-2 hours.
Loading dose: 800-1600 mg/day orally in divided doses for 1-3 weeks, then 600-800 mg/day for 1 month, then maintenance: 200-400 mg/day. IV: Loading 150 mg over 10 minutes, then 1 mg/min for 6 hours, then 0.5 mg/min.
None Documented
None Documented
5-10 hours; prolonged in renal impairment (up to 30 hours)
Terminal half-life ranges 40–70 days (mean 55 days) due to extensive tissue accumulation, particularly in adipose tissue. Prolonged half-life necessitates loading doses and long washout periods.
Renal: ~80% unchanged; biliary/fecal: <1%
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<1% unchanged). Fecal excretion accounts for ~70% of the dose. Less than 10% excreted in urine.
Category C
Category C
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)